Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025384 | 0.78 | RORC (0.35) | CYP3A4SMN1; SMN2CYP1A2TSHRHSD17B10 | |
| SCHEMBL16834276 | 0.68 | MEN1 (0.39) | CYP3A4SMN1; SMN2CYP1A2TSHRHSD17B10 | |
| SCHEMBL11490108 | 0.68 | HSD17B10 (0.41) | CYP3A4SMN1; SMN2CYP1A2TSHRHSD17B10 | |
| SCHEMBL17979817 | 0.67 | ALDH1A1 (0.47) | CYP3A4SMN1; SMN2TSHRHSD17B10MEN1 | |
| SCHEMBL31129874 | 0.67 | MEN1 (0.41) | CYP3A4SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL3926911 | 0.66 | ADRB1 (0.51) | CYP3A4SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL3787649 | 0.65 | CYP2A6 (0.48) | CYP3A4SMN1; SMN2CYP1A2TSHRHSD17B10 | |
| SCHEMBL8305765 | 0.64 | NPSR1 (0.46) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL2882677 | 0.63 | DDB1 (0.60) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7394860 | 0.62 | MEN1 (0.49) | SMN1; SMN2TSHRHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168106-A1 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-7705030-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1896454-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR -SECRETASE MODULATION | Wyeth a Corporation of the State of Delaware (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005366-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | BACE1, BACE2, APP | CYP3A4 3965/4885SMN1; SMN2 1938/4885CYP1A2 3978/4885 |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | BACE1, BACE2, APP | CYP3A4 3965/4885SMN1; SMN2 1938/4885CYP1A2 3978/4885 |
| US-20100168106-A1 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation | BACE1, BACE2, APP | CYP3A4 4524/4885SMN1; SMN2 1851/4885CYP1A2 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.